Eli Lilly Reports Strong Q4 2024 Financial Results and Provides 2025 Guidance

Details

Reported EPS increased 102% to $4.88, and non-GAAP EPS increased 114% to $5.32. The company issued 2025 revenue guidance in the range of $58.0 billion to $61.0 billion. Key events include the approval of Zepbound for obstructive sleep apnea, Omvoh for Crohn's disease, and Kisunla in China for Alzheimer's disease. The press release and financial results are furnished as Exhibit 99.1.

Items reported

Exhibits (1)

About Eli Lilly and Company

Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.